Fate Therapeutics has pioneered an off-the-shelf cellular programming platform based on engineered human induced pluripotent stem cells (iPSCs), enabling scalable production of uniform CAR T-cell and NK cell therapies targeting diverse indications including hematologic malignancies, autoimmune diseases, and solid tumors. Despite a robust intellectual property base and ongoing multi-center Phase 1 trials for lead programs like FT819, the company remains in the clinical-stage with no product revenues, sustaining large net losses annually. Cash reserves sufficed for at least a year post-2025 year-end, but ongoing R&D and manufacturing scale-up costs, combined with regulatory and litigation risks, underpin operational challenges that will shape near-term prospects.